IN THE HIGH COURT OF NEW ZEALAND AUCKLAND REGISTRY
CIV-2013-404-004338 [2016] NZHC 1885
BETWEEN DR FRANK BAILEY GELDER
First Plaintiff
PROBE INTERNATIONAL INC Second Plaintiff
AND
INNATE IMMUNOTHERAPEUTICS LIMITED
Defendant
Hearing: 9-12, 15-18 February 2016 Appearances:
B P Henry and A M Dunlop for Plaintiffs
C T Patterson and E J Grove for DefendantJudgment
15 August 2016
JUDGMENT OF COURTNEY J
This judgment was delivered by Justice Courtney on 15 August 2016 at 3.00 pm
pursuant to R 11.5 of the High Court Rules
Registrar / Deputy Registrar
Date……………………….
GELDER v INNATE IMMUNOTHERAPEUTICS LTD [2016] NZHC 1885 [15 August 2016]
Introduction
[1] In 1997 Dr Frank Gelder1 patented a method for treating viral infections in humans particularly HIV. He assigned his rights in the patented method to Probe International Inc,2 of which he is the sole director. Probe International assigned the rights to Innate Immunotherapeutics Ltd (originally called Viriyonx Corporation Ltd), of which Dr Gelder was a co-founder.3
[2] Under a Royalty and Option Agreement (ROA) Innate must pay Dr Gelder or Probe International a royalty fee in relation to the commercial use of the patented method. In this proceeding Dr Gelder and Probe International allege that Innate has failed to pay royalty fees due in respect of actual income, or benefits to which a notional income can be ascribed, from the use of the patented method.
[3] The dispute centres mainly on biological material that Innate transferred to a former employee in settlement of an employment dispute. Innate says that this material did not fall within the scope of the ROA and no royalty fees are payable in respect of it. The balance of the claim relates to biological material that Innate sold to third parties. Innate says that this material falls outside the scope of the ROA.
[4] The effect of the ROA is a matter of interpretation to which the accepted principles, summarised in Firm PI1 v Zurich Insurance Australia Insurance Ltd, apply. The Court is to ascertain “the meaning which the document would convey to a reasonable person having all the background knowledge which would reasonably have been available to the parties in the situation in which they were at the time of the contract”.4
Background
The parties
[5] Dr Gelder, a US citizen, moved to New Zealand in the late 1990s. Before then he had been working to develop a method for the treatment of HIV and had
1 The first plaintiff.
2 The second plaintiff.
3 For convenience I refer to the company as Innate throughout.
4 Firm PI1 v Zurich Insurance Australia Insurance Ltd [2014] NZSC 147, [2015] 1 NZLR 432 at
[60], citing Investors Corporation Scheme Ltd v West Bromwich Building Society [1998] 1 WLR
896 (HL) at 912; Chartbrook Ltd v Persimmon Homes Ltd [2009] UKHL 38, [2009] 1 AC 1101 at [14].
been granted patents entitled “Compositions and methods for treating viral infections”. The patented method utilised the fact that the immune system of goats (and…
Keep reading for free
Create a free CaseChat account to read Gelder v Innate Immunotherapeutics Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] NZHC 1885
- Decision Date
CaseChat Overview and Summary
The court found that the material transferred to Mr O’Loughlin in 2009 and 2011 was Product for the purposes of the ROA and, subject to the point dealt with next, the transfers of it would attract a royalty fee on the notional fair value of the material. The court found that the circumstances in which the agreement was entered into made it clear that the parties were at arm’s length. The court also found that the more straightforward aspect of Dr Gelder’s claim related to royalties payable on the sale of biological material to third parties. There was agreement between the parties regarding these sales. The gross income from them totalled NZ$167,403 and £440. The royalty payment at 3.25 per cent on these figures would be NZ$5,440.60 and £14.30. The court found that there was specific provision in clause 12 of the ROA for interest in the event of non-payment. The Default Interest Rate was specified to be 15 per cent. The court found that the invoices on which Royalty Fees were claimed were dated between April 2009 and December 2011. Interest therefore began running on each amount from 30 days after the end of the relevant quarter to the date of payment.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.